From: Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder
Subject ID | Age at placement | Seizure frequency at start of VNS | Seizure response | Side effects |
---|---|---|---|---|
A11 | Unknown | Daily | No change in seizures | None reported |
A20 | 9 years 4 months | 2–3/day | Decreased frequency and severity, decreased duration with magnet | Initial increase in frequency of seizures prior to adjustment of settings |
A21 | 6 years 3 months | 5–6/day | Decreased severity | None reported |
A24 | 1 year 9 months | Daily | Decreased frequency and severity | Swallowing difficulties |
A25 | 4 years 3 months | Daily | Minimal effect | None reported |
A26 | 4 years | Unknown | Decreased frequency | None reported |
A28 | 3 years 2 months | Daily | Decreased frequency | Initial increase in severity of seizures |
A31 | 2 years 8 months | 8–10 clusters/day | Decreased frequency, response to magnet | None reported |
A35 | 10 years | Weekly | Decreased duration | None reported |
A79 | 13 years | Unknown | Decreased duration | None reported |
B7 | 7.5 years | Daily | No change in seizures | None reported |
B8 | 5 years | Daily | No change in seizures | None reported |
B11 | Unknown | Daily | No change in seizures | None reported |
B14 | Unknown | Daily | Unknown | Unknown |
B15 | 2 years 3 months | Daily | Slight reduction in seizures | None reported |
B22 | 7 years | 10–14/day | Reduced seizures to 5–6/day | None reported |